Inhibikase begins research on IkT-148009 - a powerful new c-Abl inhibitor
 

Inhibikase Therapeutics, with funding from The Michael J. Fox Foundation, began pre-IND studies of the company's novel Abelson tyrosine kinase (c-Abl) inhibitors, IkT-148009, as a potential Parkinson's disease (PD) treatment. Inhibikase is also one of the three entities studying Nilotinib as a PD treatment.

IkT-148009, is a highly potent, first-in-class, small-molecule drug designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson's disease, with the goal of reversing disease progression. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to prevent and/or reverse the loss of dopamine-secreting neurons in the brain by restoring neuroprotective mechanisms. IkT-148009 is believed to be 50 times more brain penetrable than Nilotinib due to the small size of the molecule.

Inhibikase Wins $433, MJFF Grant to Study c-Abl Inhibitors as Parkinson's Treatment | GEN

Some more c-Abl related news
 

Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:

Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease

Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial:

Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease | Parkinson's Disease

and here is the MJFF grant record for the Inhibikase project:

Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification | Parkinson's Disease

[QUOTE=jeffreyn;1238496]Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:

Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease

Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial:


Thanks Jeffrey. The only update I would have on the above is that the MJFF et al trial is more likely to begin around Sept. Originally, the hope was mid-year (July). I also wouldn't be surprised if it pushes back a little more from there. But, it will happen, which is what matters.